Which of the following statements best describes the role of long-acting beta-agonists (LABAs) in the management of acute exacerbations in respiratory conditions?

A) LABAs are the first-line bronchodilators used during acute exacerbations.
B) LABAs are primarily indicated for maintenance therapy and are not recommended during acute exacerbations.
C) LABAs are preferred over short-acting beta-agonists for rapid relief in acute exacerbations.
D) LABAs should be used in combination with anticholinergics as the initial treatment for acute exacerbations.